{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:23:32Z","timestamp":1792808612018,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":759,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiac sarcoidosis (CS) is a potentially fatal condition that varies in its clinical presentation. Here, we describe baseline characteristics at presentation along with prognosis and predictors of outcome in a sizable and deeply phenotyped contemporary cohort of CS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Consecutive CS patients seen at one institution were retrospectively enrolled after undergoing laboratory testing, electrocardiogram, echocardiography, cardiac magnetic resonance (CMR) imaging and 18F-flourodeoxyglucose positron emission tomography (FDG-PET) at baseline. The composite endpoint consisted of all-cause mortality, aborted sudden cardiac death, major ventricular arrhythmic events, heart failure hospitalization and heart transplantation. A total of 319 CS patients were studied (67% male, 55.4\u2009\u00b1\u200912\u2009years). During a median follow-up of 2.2\u2009years (range: 1\u2009month\u201311\u2009years), 8% of patients died, while 33% reached the composite endpoint. The annualized mortality rate was 2.7% and the 5- and 10-year mortality rates were 6.2% and 7.5%, respectively. Multivariate analysis showed serum brain natriuretic peptide (BNP) levels (hazard ratio [HR] 2.41, 95% confidence interval [CI] 1.34\u20134.31, p\u2009=\u20090.003), CMR left ventricular ejection fraction (LVEF) (HR 0.96, 95% CI 0.94\u20130.98, p\u2009&amp;lt;\u20090.0001) and maximum standardized uptake value of FDG-PET (HR 1.11, 95% CI 1.04\u20131.19, p\u2009=\u20090.001) to be independent predictors of outcome. These findings remained robust for different patient subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cardiac sarcoidosis is associated with significant morbidity and mortality, particularly in those with cardiac involvement as the first manifestation. Higher BNP levels, lower LVEF and more active myocardial inflammation were independent predictors of outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3057","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T04:49:32Z","timestamp":1698209372000},"page":"2287-2298","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Predictors of Outcome in a Contemporary Cardiac Sarcoidosis Population: Role of Brain Natriuretic Peptide, Left Ventricular Function and Myocardial Inflammation"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-0928","authenticated-orcid":false,"given":"Vasileios","family":"Kouranos","sequence":"first","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital , London ,","place":["UK"]},{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajdeep S.","family":"Khattar","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Department of Echocardiography, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Okafor","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Department of Echocardiography, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Department of Cardiology, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Azzu","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Cardiac Magnetic Resonance Imaging Department, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Arun","family":"Baksi","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Cardiac Magnetic Resonance Imaging Department, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshama","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Nuclear Medicine Department, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Cowie","sequence":"additional","affiliation":[{"name":"King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol Umfrey","family":"Wells","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital , London ,","place":["UK"]},{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Department of Cardiology, Royal Brompton Hospital , London ,","place":["UK"]},{"name":"King's College London , London ,","place":["UK"]},{"name":"Center for Molecular Cardiology, Schlieren Campus, University of Zurich , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Department of Cardiology, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"2026010913105240500_ejhf3057-bib-0001","first-page":"736","article-title":"Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913105240500_ejhf3057-bib-0002","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913105240500_ejhf3057-bib-0003","first-page":"372","article-title":"Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan","volume":"43","author":"Iwai","year":"1993","journal-title":"Acta Pathol Jpn"},{"key":"2026010913105240500_ejhf3057-bib-0004","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1378\/chest.07-2784","article-title":"Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing","volume":"133","author":"Mehta","year":"2008","journal-title":"Chest"},{"key":"2026010913105240500_ejhf3057-bib-0005","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","article-title":"Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis","volume":"10","author":"Kouranos","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010913105240500_ejhf3057-bib-0006","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"2026010913105240500_ejhf3057-bib-0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2012.10.021","article-title":"CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis","volume":"6","author":"Greulich","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010913105240500_ejhf3057-bib-0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis","volume":"63","author":"Blankstein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913105240500_ejhf3057-bib-0009","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis","volume":"21","author":"Ahmadian","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"2026010913105240500_ejhf3057-bib-0010","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"2026010913105240500_ejhf3057-bib-0011","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25\u2009years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation"},{"key":"2026010913105240500_ejhf3057-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.006145","article-title":"Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block","volume":"11","author":"Nordenswan","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026010913105240500_ejhf3057-bib-0013","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: A 20-year experience in two tertiary care centres","volume":"20","author":"Fussner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913105240500_ejhf3057-bib-0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjcard.2020.04.025","article-title":"Risk of adverse cardiovascular events in cardiac sarcoidosis independent of left ventricular function","volume":"127","author":"Rosenthal","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026010913105240500_ejhf3057-bib-0015","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/eurheartj\/ehz428","article-title":"Sudden death in cardiac sarcoidosis: An analysis of nationwide clinical and cause-of-death registries","volume":"40","author":"Ekstr\u00f6m","year":"2019","journal-title":"Eur Heart J"},{"key":"2026010913105240500_ejhf3057-bib-0016","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026010913105240500_ejhf3057-bib-0017","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.hrthm.2017.10.036","article-title":"2017 AHA\/ACC\/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"2026010913105240500_ejhf3057-bib-0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms","volume":"2","author":"Schiller","year":"1989","journal-title":"J Am Soc Echocardiogr"},{"key":"2026010913105240500_ejhf3057-bib-0019","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12350-018-1447-9","article-title":"Stop that glucose getting to the heart!","volume":"27","author":"Wechalekar","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"2026010913105240500_ejhf3057-bib-0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11307-006-0075-y","article-title":"Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues","volume":"9","author":"Wang","year":"2007","journal-title":"Mol Imaging Biol"},{"key":"2026010913105240500_ejhf3057-bib-0021","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"2026010913105240500_ejhf3057-bib-0022","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0735-1097(02)02715-8","article-title":"A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis","volume":"41","author":"Okura","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026010913105240500_ejhf3057-bib-0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9343(77)90121-8","article-title":"Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11)","volume":"63","author":"Roberts","year":"1977","journal-title":"Am J Med"},{"key":"2026010913105240500_ejhf3057-bib-0024","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1749-6632.1986.tb18531.x","article-title":"The prognosis of sarcoid heart disease in the United Kingdom","volume":"465","author":"Fleming","year":"1986","journal-title":"Ann N\u2009Y Acad Sci"},{"key":"2026010913105240500_ejhf3057-bib-0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.128.1.30","article-title":"Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands","volume":"128","author":"Smedema","year":"2005","journal-title":"Chest"},{"key":"2026010913105240500_ejhf3057-bib-0026","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1093\/eurheartj\/ehac323","article-title":"Risk stratification of patients with cardiac sarcoidosis: The ILLUMINATE-CS registry","volume":"43","author":"Nabeta","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913105240500_ejhf3057-bib-0027","first-page":"1653","article-title":"Systematic review for the 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology\/American Heart Association Task force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"72","author":"Kusumoto","year":"2018","journal-title":"Circulation"},{"key":"2026010913105240500_ejhf3057-bib-0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003040","article-title":"Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis","volume":"5","author":"Ekstr\u00f6m","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026010913105240500_ejhf3057-bib-0029","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12350-021-02567-0","article-title":"Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET","volume":"28","author":"Yamamoto","year":"2021","journal-title":"J Nucl Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/12\/2287\/65554114\/eurjhf_25_12_2287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/12\/2287\/65554114\/eurjhf_25_12_2287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:13:37Z","timestamp":1767982417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/12\/2287\/8341924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,11,7]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3057","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"2023-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}